SecBot SecBot
SECBOTREPLAY Home › Report › FTH

FTH · Phase 2 PIKTOR 33% ORR

Faeth Therapeutics, Inc. · 8-K filed Nov 9, 2026 at 07:19 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 07:19 ET

Faeth Therapeutics announced positive preliminary Phase 2 topline results for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer. The trial met its primary endpoint with a 33% confirmed ORR and 7.4-month median PFS in a heavily pretreated population. The company plans to advance to a Phase 3 registrational trial, subject to regulatory alignment.

  • Confirmed ORR of 33% (12 of 36 efficacy-evaluable patients) in advanced endometrioid endometrial cancer
  • Among PIK3CA-mutation patients, confirmed ORR was 44% (7 of 16)
  • Preliminary median PFS of 7.4 months (95% CI 5.3-NR) and 6-month PFS rate of 62%
  • Disease control rate (DCR) of 83% (30 of 36)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access